Avastin (bevacizumab) in the treatment of tumors of the stomach and pancreas
- Authors: Semenov N.N1
-
Affiliations:
- Issue: No 18 (2012)
- Pages: 20-24
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279994
- ID: 279994
Cite item
Open Access
Access granted
Abstract
The article considers the results of phases II and III clinical trials on the application of targeted therapy with bevacizumab (Avastin) for tumors of the stomach and pancreas. It was shown that the combination of Avastin with chemotherapy significantly improves the control of tumor growth and improves time to progression, without increasing overall survival in metastatic gastric cancer. However, adding Avastin to chemotherapy has showed distinct advantages in patients with certain morphological types of tumors. In cancer of the pancreas, encouraging results of phase II trials have not been confirmed in a randomized trial, but the latter has identified serum markers predicting effectiveness of chemotherapy in combination with Avastin.
Keywords
Full Text
References
- Трякин А.А. Авастин (бевацизумаб) в лечении рака толстой кишки: 5-летний мировой опыт // Онкологическая колопроктология 2011. № 1. С. 26-31.
- Борисова Е.И., Гуторов С.Л., Чичиков Е.И., Денисенко А.Л. Поиск маркеров эффективности бевацизумаба при метастатическом раке толстой кишки // Фарматека 2011. №17. C. 44-46.
- El-Rayes B.F., Zalupski M., Bekai-Saab T., et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010;21(10):1999-2004.
- Shah M.A., Jhawer M., Ilson D.H., et al. Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma. J Clin Oncol 2011;29:868-74.
- Okines A.F., Langley R., Cafferty F.H., et al. Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizum ab (B) in patients (pts) with gastric or oesopha gogastric junction (OGJ) adenocarcinoma. J Clin Oncol 2010. ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2010;28(15):4019.
- Ohtsu A., Shah M.A., Van Cutsem E., et al. Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase HI Study. J Clin Oncol 2011;29:3968-76.
- Shah M.A., Cutsem E.V., Kang Y.-K., et al. Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer. J Clin Oncol 2012;30(4),suppl:5.
- Kindler H.L., Friberg G., Singh D.A., et al. Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer. J Clin Oncol 2005;23(31):8033-40.
- Ko A.H., Dito E., Schillinger B., et al. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs 2008;26(5):463-71.
- Fogelman D., Jafari M., Varadhachary G.R., et al. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 2011;68(6):1431-38.
- Iyer R.V., Yu J., Garrett C.R., et al. Multicenter phase II study of gemcitabine, capecitabine, and bevacizumab in patients with advanced pancreatic cancer (APC): Final analysis of clinical and quality of life endpoints. J Clin Oncol, 2008;26(15S):4616.
- Kindler H.L., Niedzwiecki D., Hollis D., et al. Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2009;27:2231-37.
- Kindler H.L., Ioka T., Richel D.J., et al. A doubleblinded, placebo-controlled, randomised, phase III study of axitinib (AG-013736) plus gemcitabine versus placebo in advanced pancreatic cancer patients. Eur J Cancer 2009;7:361, abstr 6502.
- Phase 3 trial of aflibercept in metastatic pancreatic cancer discontinued. http://en.sanofi-aventis.com/press/press_releases/2009/ ppc_26186.asp.
- Nixon A.B., Pang H., Starr M., et al. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB80303. J Clin Oncol 2011; 29(15): 10508.
- Small W. Jr., Mulcahy M.F., Rademaker A., et al. Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer. Int J Radiat Oncol Biol Phys 2011;80(2): 476-82.
- Van Buren G., Ramanathan R.K., Krasinskas A.M., et al. Phase II trial of fixed-dose rate gemcitabine, bevacizumab, and concurrent 30 gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. J Clin Oncol 2012;30(4):258.
- Crane C.H., Winter K., Regine W.F., et al. Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 2009;27(25):4096-102.
Supplementary files
